Hermetica Superfood Encyclopedia
The Short Answer
Pleurotus columbinus fruiting bodies contain phenolic acids (gallic acid, chlorogenic acid), flavonoids (catechin 7.60–26.90 µg/mL, epicatechin 5.69–11.98 µg/mL), ergothioneine, ergosterol, and lovastatin that collectively scavenge free radicals and disrupt microbial membranes. In vitro antioxidant assays demonstrate DPPH EC50 values of 2.25–4.98 µg/mL and antimicrobial activity against dermatophytes including Trichophyton rubrum at MIC values as low as 16.17 µg/mL, though no human clinical trials have yet validated these effects.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordPleurotus columbinus benefits
Columbinus Oyster Mushroom — botanical close-up
Health Benefits
**Antioxidant Activity**
Methanolic extracts exhibit potent free radical scavenging, with DPPH EC50 of 2.25–4.98 µg/mL and ABTS EC50 of 4.34–6.16 µg/mL, attributable to catechin, epicatechin, gallic acid, and ergothioneine content.
**Antimicrobial Potential**
Extracts inhibit clinically relevant dermatophytes such as Trichophyton rubrum (MIC 16.17–200 µg/mL) and T. tonsurans (MIC 89.68–129.37 µg/mL), as well as Candida species, likely through disruption of fungal cell membranes or key enzymatic targets.
**Cardiovascular Support (Preclinical Basis)**
Lovastatin identified in fruiting body extracts may contribute to cholesterol biosynthesis inhibition via HMG-CoA reductase suppression, paralleling effects observed with lovastatin from Pleurotus ostreatus, though species-specific quantification and human data are absent.
**Provitamin D2 Supply**
Ergosterol present in fruiting bodies serves as a precursor to vitamin D2 (ergocalciferol) upon ultraviolet light exposure, supporting potential contributions to bone metabolism and immune modulation consistent with broader Pleurotus genus data.
**Anti-inflammatory Potential (Inferred)**
Phenolic and flavonoid constituents identified by UHPLC-QTOF-MS profiling of 97 metabolites are associated with suppression of pro-inflammatory mediators in related Pleurotus species, including reductions in IL-6 and modulation of TNF-α signaling pathways.
**Cytoprotective Effects (Related Species Data)**
Ergothioneine, a histidine-derived antioxidant amino acid concentrated in fungal tissue, provides mitochondrial and cellular protection against oxidative stress; its presence in P. columbinus extracts suggests analogous cytoprotective capacity.
**Nutritional Density**
Fruiting bodies supply high-quality protein, dietary fiber (including β-glucans), B vitamins, and trace minerals, offering a nutrient-dense food matrix that supports metabolic health consistent with the broader edible Pleurotus category.
Origin & History
Natural habitat
Pleurotus columbinus is a species within the oyster mushroom (Pleurotus) genus, naturally occurring on decaying hardwood across temperate regions of Europe and parts of Asia. Like other Pleurotus species, it thrives on lignocellulosic substrates and has been cultivated experimentally on agri-food residues such as wheat straw, vine shoots, and cottonseed hulls under controlled humidity and temperature conditions. Commercial and research cultivation typically exploits its saprophytic nature to produce fruiting bodies for nutritional and bioactive compound analysis.
“Pleurotus columbinus does not feature independently in classical ethnobotanical or traditional medicine records, and its historical use is subsumed within the broader category of wild and cultivated oyster mushrooms consumed across East Asia, Europe, and the Mediterranean for at least several centuries. Oyster mushrooms of the Pleurotus genus have been cultivated in China since at least the Tang Dynasty (618–907 CE), valued as both food and tonic fungi in traditional Chinese dietary practice, though species-level distinctions were not maintained in historical texts. In European folk traditions, wild Pleurotus species were gathered opportunistically from beech and elm trees as a seasonal woodland food, with no documented medicinal application specific to P. columbinus. Modern scientific interest in the species has emerged primarily from the early 21st century as researchers explored cultivated strains grown on agricultural by-products to characterize bioactive metabolite profiles and valorize food waste streams.”Traditional Medicine
Scientific Research
The current evidence base for Pleurotus columbinus is limited exclusively to in vitro and phytochemical characterization studies, with no published human clinical trials or animal intervention studies identified in the available literature. The most substantive data derive from HPLC-DAD-MS and UHPLC-QTOF-MS phytochemical profiling studies of methanolic fruiting body extracts grown on varied agri-food substrates, identifying 97 metabolites and quantifying key phenolics at concentrations of 1.10–26.90 µg/mL. Antimicrobial MIC determinations against a panel of yeasts, bacteria, and dermatophytes and antioxidant EC50 assays (DPPH, ABTS, linoleic acid oxidation) represent the full scope of functional bioactivity data currently available. Extrapolation from better-studied congeners such as P. ostreatus—where cytotoxicity IC50 of 4.5 µg/mL against MCF-7 breast cancer cells and selectivity index of 13.4 versus normal Vero cells have been reported—provides mechanistic hypotheses but cannot substitute for species-specific evidence.
Preparation & Dosage
Traditional preparation
**Fresh Fruiting Bodies (Culinary)**
50–150 g per serving); no therapeutic dose established
Consumed as food in quantities typical of edible oyster mushrooms (.
**Dried Powder**
Fruiting bodies are dried and powdered for research extraction; no standardized supplemental dose defined for P. columbinus specifically.
**Methanolic Extract (Research Use)**
In vitro assays utilize concentrations of 2–200 µg/mL; these concentrations are not directly translatable to oral supplemental dosing without bioavailability data.
**Hot Water Extract (β-Glucan-Rich, By Analogy)**
Related Pleurotus species are extracted with hot water to yield β-glucan-enriched fractions; standardization to β-glucan content (typically 20–40% in Pleurotus genus products) is common in commercial mushroom supplements but not validated for P. columbinus.
**Standardized Extracts (Genus-Level Context)**
Oyster mushroom supplements on the market are often standardized to polysaccharide content (30–50%); no P. columbinus-specific product standardization exists.
**Timing**
No pharmacokinetic data available; general mushroom supplement guidance suggests consumption with meals to improve tolerability and potential fat-soluble compound absorption (e.g., ergosterol, lovastatin).
Nutritional Profile
Pleurotus columbinus fruiting bodies, consistent with the broader Pleurotus genus, contain approximately 25–35% protein on a dry weight basis with a favorable amino acid profile including all essential amino acids. Dietary fiber, including immunomodulatory β-glucans (estimated 20–35% dry weight in genus), constitutes a major carbohydrate fraction alongside chitin in the cell wall. Key micronutrients include B vitamins (riboflavin, niacin, pantothenic acid), potassium, phosphorus, copper, and selenium. Ergosterol concentrations vary with UV exposure and substrate, serving as a vitamin D2 precursor; ergothioneine is present as a specialized antioxidant amino acid with high bioavailability in humans via the OCTN1 transporter. Phenolic compounds (catechin 7.60–26.90 µg/mL, gallic acid 1.29–2.76 µg/mL in methanolic extracts), lovastatin, and chlorogenic acid (1.10–1.62 µg/mL) contribute to the functional phytochemical matrix. Fat content is low (2–5% dry weight), with linoleic acid as a predominant fatty acid.
How It Works
Mechanism of Action
The antioxidant activity of Pleurotus columbinus is mediated primarily through hydrogen atom transfer and single electron transfer mechanisms driven by its phenolic hydroxyl groups; catechin and epicatechin donate electrons directly to DPPH and ABTS radicals, while gallic acid's pyrogallol moiety contributes additional reducing capacity. Ergothioneine, a thiohistidine betaine, acts as a dedicated mitochondrial antioxidant by scavenging reactive oxygen and nitrogen species and chelating redox-active metal ions, providing a distinct non-phenolic antioxidant pathway. Antimicrobial effects against Candida and dermatophyte species are attributed to membrane disruption by lipophilic phenolics and potential inhibition of fungal ergosterol biosynthesis enzymes, though precise target enzymes have not been experimentally mapped for this species. Lovastatin, identified in extracts, competitively inhibits HMG-CoA reductase (the rate-limiting enzyme in the mevalonate pathway), reducing endogenous cholesterol synthesis, a mechanism well-characterized for this compound in pharmaceutical contexts but unvalidated at the concentrations present in P. columbinus fruiting bodies.
Clinical Evidence
No clinical trials in human subjects have been conducted for Pleurotus columbinus as of the available research record, making it impossible to summarize effect sizes, confidence intervals, or therapeutic outcomes in a clinical context. In vitro antioxidant assays constitute the strongest functional evidence, demonstrating reproducible DPPH EC50 values between 2.25 and 4.98 µg/mL across different substrate-grown extract batches, indicating consistent bioactivity. Antimicrobial testing against Trichophyton rubrum (MIC as low as 16.17 µg/mL) and Candida tropicalis (MIC 79.37 µg/mL) provides preliminary data of potential therapeutic relevance for topical antifungal applications, but in vitro MIC values do not directly translate to clinical efficacy without pharmacokinetic and pharmacodynamic validation. The overall clinical evidence is insufficient to establish therapeutic indications, effective doses, or safety thresholds, and all current findings should be regarded as hypothesis-generating rather than practice-informing.
Safety & Interactions
No formal toxicological studies, adverse event reports, or drug interaction data specific to Pleurotus columbinus have been published, and the absence of such data prevents definitive safety characterization beyond the general culinary safety of edible Pleurotus species. The presence of lovastatin in fruiting body extracts warrants theoretical caution regarding additive effects when consumed alongside pharmaceutical statin drugs (HMG-CoA reductase inhibitors) or CYP3A4-metabolized medications, as lovastatin is a CYP3A4 substrate; the relevant concentrations in food-form consumption are likely sub-therapeutic but remain unquantified for this species. Individuals with known hypersensitivity to basidiomycete fungi or mold allergies should exercise caution, as cross-reactive allergens are documented across the Pleurotus genus. Pregnancy and lactation safety is unstudied; culinary consumption as a food is generally considered low risk, but concentrated extracts or supplements should be avoided in these populations until evidence establishes safety.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Pleurotus columbinusColumbinus oyster mushroomBlue oyster mushroom (informal, regional)Pleurotus ostreatus var. columbinus
Frequently Asked Questions
What are the main bioactive compounds in Pleurotus columbinus?
Pleurotus columbinus fruiting body extracts contain catechin (7.60–26.90 µg/mL), epicatechin (5.69–11.98 µg/mL), gallic acid (1.29–2.76 µg/mL), chlorogenic acid, hydroxytyrosol, ergosterol, ergothioneine, and lovastatin, as identified by HPLC-DAD-MS and UHPLC-QTOF-MS analysis of 97 total metabolites. These compounds collectively account for the mushroom's in vitro antioxidant, antimicrobial, and potential cardiovascular bioactivities, though human data validating physiological relevance at dietary doses remain unavailable.
Does Pleurotus columbinus have antimicrobial properties?
In vitro studies demonstrate that methanolic extracts of P. columbinus inhibit clinically relevant fungi including Trichophyton rubrum (MIC 16.17–200 µg/mL), T. tonsurans (MIC 89.68–129.37 µg/mL), Candida tropicalis (MIC 79.37–>200 µg/mL), and C. albicans (MIC 125.99–>200 µg/mL). These effects are attributed to phenolic compounds disrupting microbial cell membranes or inhibiting key enzymes, but no clinical antimicrobial trials in humans have been conducted to translate these findings into therapeutic recommendations.
Are there any clinical trials on Pleurotus columbinus in humans?
No human clinical trials have been published for Pleurotus columbinus as of the current research record; all available evidence is derived from in vitro phytochemical characterization and bioactivity assays. Broader evidence from the Pleurotus genus, including P. ostreatus studies, provides mechanistic context but cannot be directly applied to P. columbinus without species-specific clinical investigation. Consumers and clinicians should treat this ingredient as a research-stage compound rather than a clinically validated supplement.
Is Pleurotus columbinus safe to consume, and does it interact with any medications?
As an edible oyster mushroom species, P. columbinus is considered generally safe for culinary consumption, consistent with other Pleurotus species widely eaten globally. However, the presence of lovastatin in fruiting body extracts raises a theoretical interaction concern with pharmaceutical statin drugs and CYP3A4-metabolized medications; concentrations in food-form consumption are likely low but have not been quantified. Individuals with mushroom or mold allergies and those taking statin medications should consult a healthcare provider before using concentrated extracts.
What is the recommended dose of Pleurotus columbinus supplements?
No established supplemental dose exists for Pleurotus columbinus, as no clinical trials have defined effective or safe dose ranges in humans. Research studies employ methanolic extract concentrations of 2–200 µg/mL for in vitro assays, which are not directly translatable to oral dosing. By analogy with related Pleurotus species sold as functional mushroom supplements, products standardized to 30–50% polysaccharides are commonly dosed at 500–3000 mg dried extract daily, but these figures have not been validated specifically for P. columbinus.
How does Pleurotus columbinus compare to other medicinal mushrooms for antioxidant protection?
Pleurotus columbinus demonstrates exceptional antioxidant potency with DPPH EC50 values of 2.25–4.98 µg/mL, placing it among the most effective mushroom species for free radical scavenging. Its antioxidant capacity is driven by high concentrations of catechin, epicatechin, gallic acid, and ergothioneine—compounds that rival or exceed those found in other popular medicinal mushrooms like reishi or lion's mane. This makes it particularly valuable for individuals seeking concentrated antioxidant support from a fungal source.
Can Pleurotus columbinus supplements help with fungal skin infections like athlete's foot or ringworm?
Pleurotus columbinus extracts show inhibitory activity against clinically relevant dermatophytes including Trichophyton rubrum and T. tonsurans, with minimum inhibitory concentrations (MIC) in the range of 16.17–200 µg/mL. While these laboratory results are promising, most research to date involves in vitro studies rather than human clinical trials on skin infections. Anyone considering this mushroom for dermatophyte-related concerns should consult a healthcare provider, as topical or systemic antifungal medications remain the evidence-based first-line treatment.
What is the best form of Pleurotus columbinus supplement—powder, extract, or whole fruiting body?
Methanolic and other solvent-based extracts of Pleurotus columbinus demonstrate superior antioxidant bioavailability compared to whole fruiting body preparations, with EC50 values indicating concentrated potency of bioactive compounds. Standardized extracts allow for consistent dosing of active constituents like ergothioneine and polyphenols, whereas whole mushroom powders may deliver variable nutrient profiles depending on growing conditions and processing methods. For maximum antioxidant efficacy, standardized mushroom extracts typically outperform non-standardized whole mushroom powders in supplement applications.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w pleurotus-columbinus-pleurotus-columbinus curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
